14 completed, 14 unknown, 3 recruiting, 2 active not recruiting. 8 Not applicable, 4 Phase 2, 4 Phase 3, 2 Phase 1, 1 Phase 4.
Follow Reinfection: new trials by email Literature Review of Reinfection trials Research Report on Reinfection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection FMT (fecal microbiota transplantation), Fidaxomicin, Vancomycin (VAN) treatment - Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence | Not applicable | Not yet recruiting | Medical University of Warsaw | 424 | 2025-10-01 | 2025-08-13 |
| Probiotics in the Prevention of Recurrent Prosthetic Joint Infection of the Hip and Knee Probiotic, Standard of care - Prosthetic-joint Infection, Dysbiosis | Phase 4 | Enrolling by invitation | Boston Medical Center | 152 | 2025-08-15 | 2026-08-26 |
| Clinicaly Manifested Reinfections with Borrelia Burgdorferi Sensu Lato Lyme Borreliosis | Active not recruiting | University Medical Centre Ljubljana | 15000 | 2024-12-31 | 2025-02-21 | |
| Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients EXL01, Placebo - Clostridioides Difficile Infection, Recurrent Infection | Phase 1 / Phase 2 | Recruiting | Hospices Civils de Lyon | 56 | 2024-05-07 | 2026-10-20 |
| Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection Fecal filtrate transplantation, Conventional fecal microbiota transplantation - Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection | Phase 3 | Unknown | University of Pecs | 238 | 2023-11-01 | 2023-05-19 |
| Nettle and Cranberry Capsules for Prevention of Urinary Tract Infection Nettle and Cranberry complex capsules, Placebo(starch) - Urinary Tract Infection | Not applicable | Completed | Chung Shan Medical University | 60 | 2023-07-05 | 2025-09-26 |
| Long COVID and Its Associations With Health Outcomes in Older Adults no interventions - Long COVID, COVID-19 Pandemic | Active not recruiting | Peking University | 11527 | 2023-04-24 | 2024-12-12 | |
| Reinfection and Re-revision Rates of Periprosthetic Knee Infection Under Four Different Surgical Strategies Total Knee Arthroplasty, Reinfection | Completed | First Affiliated Hospital of Fujian Medical University | 200 | 2023-01-01 | 2025-11-18 | |
| Characteristics of SARS-CoV-2 Reinfection COVID-19 | Unknown | Jiming Zhang | 1144 | 2022-12-15 | 2023-02-28 | |
| Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men Behavioural intervention, HCV RNA home-based test - Hepatitis C Virus Infection | Not applicable | Unknown | Public Health Service of Amsterdam | 258 | 2021-09-14 | 2024-08-02 |
| Comparison of Efficacy of Two Combination Regimens for the Neisseria Gonorrhoeae and Chlamydia Coinfection Ceftriaxone 1000mg + doxycycline 100 mg, Cefixime 800mg + doxycycline 100 mg - Neisseria Gonorrhoeae Infection, Chlamydia Trachomatis Infection | Phase 2 | Completed | Haiphong University of Medicine and Pharmacy | 125 | 2021-07-15 | 2022-03-17 |
| A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection Posaconazole 100 MG [Noxafil], Posaconazole 40 MG/ML - Cystic Fibrosis, Aspergillosis | Phase 2 / Phase 3 | Unknown | Bambino Gesù Hospital and Research Institute | 135 | 2021-04-22 | 2021-07-19 |
| HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of | Unknown | National Taiwan University Hospital | 300 | 2021-02-09 | 2021-02-26 | |
| HCV Reinfection in HD Patients Achieving SVR Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of | Unknown | National Taiwan University Hospital | 350 | 2021-02-01 | 2021-02-24 | |
| Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients CLIA of IgG and IgM against SARS-Cov-2 - Liver Transplant Infection, Covid19 | Unknown | Magdalena Salcedo | 300 | 2020-05-29 | 2020-06-02 | |
| RT-PCR Database Analysis for COVID-19 Infections and Re-infection Covid-19, SARS-CoV Infection | Unknown | University Hospital, Montpellier | 7000000 | 2020-02-01 | 2022-01-04 | |
| Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence H56:IC31, Placebo - Tuberculosis, Pulmonary | Phase 2 | Completed | International AIDS Vaccine Initiative | 831 | 2019-01-31 | 2026-02-24 |
| The Situation of Re-infection of Helicobacter Pylori After Successful Eradication Helicobacter Pylori | Unknown | Shandong University | 1800 | 2018-09-01 | 2019-07-23 | |
| Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings Hepatitis C, Chronic | Completed | Kirby Institute | 140 | 2018-08-17 | 2022-04-14 | |
| Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs AiCure, AiCure with gamification - Hepatitis C, Medication Adherence | Not applicable | Completed | Albert Einstein College of Medicine | 11 | 2017-11-14 | 2021-09-14 |
Showing 20 of 35. Sign in to see all of them.
Hepatitis C (5) · COVID-19 (4) · Clostridium Infections (4) · Recurrence (4) · Hepatitis C, Chronic (3) · Primary Immunodeficiency Diseases (3) · Behavior, Addictive (2) · Directly Observed Therapy (2) · Liver Diseases (2) · Medication Adherence (2) · Tuberculosis (2) · Abscess (1) · Acquired Immunodeficiency Syndrome (1) · Agammaglobulinemia (1)
Disease Attributes (35) · Pathologic Processes (35) · Pathological Conditions, Signs and Symptoms (35) · Recurrence (31) · Infections (25) · Bacterial Infections and Mycoses (12) · Virus Diseases (11) · Bacterial Infections (10) · RNA Virus Infections (10) · Digestive System Diseases (9) · Communicable Diseases (8) · Lung Diseases (8) · Respiratory Tract Diseases (8) · Blood-Borne Infections (7) · Gram-Positive Bacterial Infections (7)
Vancomycin (2) · Anti-Bacterial Agents (1) · Cefixime (1) · Ceftriaxone (1) · Doxycycline (1) · Fecal Microbiota Transplantation (1) · Fidaxomicin (1) · Patient Navigation (1) · Pneumococcal Vaccines (1) · Probiotics (1) · Standard of Care (1) · Suspensions (1) · Therapeutics (1) · hepatitis B hyperimmune globulin (1) · posaconazole (1)
National Taiwan University Hospital (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Albert Einstein College of Medicine (1) · Bambino Gesù Hospital and Research Institute (1) · Baylor College of Medicine (1) · Boston Medical Center (1) · Chung Shan Medical University (1) · Copenhagen University Hospital, Rigshospitalet (1) · First Affiliated Hospital of Fujian Medical University (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Goztepe Training and Research Hospital (1) · Groupe Hospitalier Diaconesses Croix Saint-Simon (1) · Haiphong University of Medicine and Pharmacy (1) · Hospices Civils de Lyon (1) · Instituto Grifols, S.A. (1)
United States (9) · China (5) · France (5) · Taiwan (4) · Spain (3) · Italy (2) · Netherlands (2) · Australia (1) · Canada (1) · Czechia (1) · Denmark (1) · Germany (1) · Greece (1) · Hungary (1) · Ireland (1)
Chen-Hua Liu, MD (2) · Adilia Warris, Prof (1) · Alain Litwin, MD, MPH (1) · Ayesha Abdeen, MD (1) · David Pei-Cheng Lin, PhD (1) · Dina Kao, MD (1) · Harry L Malech, M.D. (1) · Jann-Yuan Wang, MD (1) · Jason Grebely (1) · Jiming Zhang, PhD (1) · John W Sleasman, MD (1) · Jose Molina Gil-Bermejo, MD. PhD (1) · Jue Liu, Ph.D (1) · Julia Arnsten, MD (1) · Liu Zhang (1)
PMID 20489056, PMID 24077845, PMID 24762631, PMID 33106983, PMID 33631102, PMID 34150673, PMID 35810277, PMID 36370741, PMID 36922871, PMID 37150144, PMID 38103458, PMID 38242324, PMID 39186268, PMID 39475112, PMID 40056922, PMID 40178760, PMID 41124945, PMID 41703273, PMID 42015166, PMID 42482138, PMID 42606118, PMID 42753987, PMID 8609130
2019 (1), 2023 (1)